Abstract: Controlled release of active agents from sustained release push delivery devices having high drug loading are described wherein residual drug content in the device is minimized by the utilization of a flow-promoting layer between a semi-permeable wall and drug layer comprising the device.
Abstract: The invention disclosed comprises a method for administering the antidiabetic drug glipizide to a patient in need of glipizide in need of antidiabetic therapy.
Type:
Grant
Filed:
January 11, 1994
Date of Patent:
March 26, 2002
Assignee:
Alza Corporation
Inventors:
Anthony L. Kuczynski, Atul Devolatt Ayer, Patrick S. L. Wong
Abstract: The invention provides a method for adjusting, i.e., varying, the rate of delivery of a therapeutic agent through a body surface from an electrotransport assembly of the type which includes a predetermined, e.g., fixed, output electronic controller and a detachable therapeutic agent source. The method provides a plurality of therapeutic agent sources in which a single parameter or a series of parameters has been varied. The plurality of agent sources are supplied, one at a time, to the controller of the electrotransport assembly, so that together (i.e., source and controller) the agent delivery rate is varied.
Abstract: Controlled release of liquid, active agent formulations is provided by dispersing porous particles containing the liquid active agent formulation in osmotic, push-layer dosage forms. The dosage forms may provide for continuous or pulsatile delivery of active agents.
Type:
Grant
Filed:
December 22, 1999
Date of Patent:
January 29, 2002
Assignee:
Alza Corporation
Inventors:
Patrick S. -L. Wong, David E. Edgren, Liang C. Dong, Crystal Pollock-Dove
Abstract: Method of making an electrotransport device containing an analog of a parent polypeptide having one or more amino acid residues substituted relative to the parent polypeptide with an amino acid residue selected from the group consisting of proline, glycine and asparagine.
Abstract: An electrotransport device (10) for the electrotransport delivery of agents having at least one hydrophobic site thereon, such as peptides and proteins, contains donor and counter electrodes (12, 16 and 14, 18), a power source and electrical control circuitry (24). The donor electrode (12, 16) contains, in addition to the agent, an electrotransport enhancer such as non-ionic surfactants or zwitterionic surfactants without a net charge. A method of increasing electrotransport flux of agent shaving at least one hydrophobic site thereon utilizes non-ionic or zwitterionic surfactants in the solution or suspension containing the agent. A method for the electrotransport delivery of an agent with at least one hydrophobic site through a body surface relies on the incorporation of a non-ionic surfactant or a zwitterionic surfactant without a net charge, into the solution or suspension containing the agent to decrease its hydrophobicity.
Type:
Grant
Filed:
June 18, 1997
Date of Patent:
December 11, 2001
Assignee:
Alza Corporation
Inventors:
Leslie A. Holladay, Lynda G. Treat-Clemons, Patricia Margaret Bassett
Abstract: The invention is directed to a composition and product for use in an electrotransport device. The composition includes an ionized drug, an anti-inflammatory agent and a solvent. Preferably, the anti-inflammatory agent is hydrocortisone or esters thereof, and the solvent is water and a material such as an alcohol, a glycol, a glycerol, a cyclodextrin, a nonionic surfactant and/or mixtures thereof.
Type:
Grant
Filed:
June 26, 1998
Date of Patent:
November 27, 2001
Assignee:
ALZA Corporation
Inventors:
Philip W. Ledger, Michel J. N. Cormier, Patricia S. Campbell
Abstract: A device (3) comprising a sheet member (6) having a plurality of microprotrusions (4) for penetrating the skin and a rigid support (15) contacting and extending across the sheet member (6) for transmitting an applied force evenly across the length and width of the sheet member (6) to reproducibly and reliably penetrate the skin with the microprotrusions (4).
Type:
Grant
Filed:
December 9, 1998
Date of Patent:
November 27, 2001
Assignee:
ALZA Corporation
Inventors:
Joseph Creagan Trautman, Patrick S.-L. Wong, Peter E. Daddona, Hyunok Lynn Kim, Michael G. Zuck
Abstract: An iontophoretic delivery device (10) is provided. Device (10) has an electronic circuit (32) having electronic components such as batteries (30) mounted thereon. Device (10) also includes a pair of electrode assemblies (18, 19). The electronic circuit (32) is electrically connected to the electrode assemblies (18, 19) using an electrically conductive adhesive (34). The adhesive can also be used to electrically connect two or more electronic components within circuit (32) or to connect an electronic component to the electronic circuit (32). In one practice of the invention, the electrically conductive adhesive (44) functions as an electrode and electrically connects the circuit (32) to an agent-containing reservoir (24, 25). In a further practice of the invention, the electrically conductive adhesive (93) functions as an agent reservoir and contains the agent to be iontophoretically delivered.
Type:
Grant
Filed:
December 2, 1994
Date of Patent:
November 13, 2001
Assignee:
Alza Corporation
Inventors:
Ronald P. Haak, J. Richard Gyory, Robert M. Myers, Felix A. Landrau, Harold F. Sanders, Lothar W. Kleiner, Linda M. Hearney
Abstract: Methods for modifying polypeptide agents to enhance their transdermal electrotransport flux are provided. The polypeptide is modified by reducing the potential of the polypeptide for forming &agr;-helical or &bgr;-sheet segments. In particular, amino acid residues known to stabilize &agr;-helical and &bgr;-sheet segments can be replaced with destabilizing residues and known helix breakers. Modified molecules and compositions including the molecules are also provided.
Abstract: The invention relates to formulations for the electrically assisted transdermal delivery of lidocaine and epinephrine. The present invention further provides methods and devices for the electrically assisted delivery of local anesthetics, preferably lidocaine.
Type:
Grant
Filed:
November 14, 1997
Date of Patent:
September 25, 2001
Assignee:
Alza Corporation
Inventors:
Andreas Linkwitz, Ivan W. Chin, J. Richard Gyory, Ronald V. Thompson, Paul J. Urbanski
Abstract: This invention pertains to a dosage form for the management of epilepsies wherein the dosage form comprises administering valproic acid or a valproic acid derivative at a continuous rate over an extended time.
Type:
Grant
Filed:
May 28, 1993
Date of Patent:
September 11, 2001
Assignee:
Alza Corporation
Inventors:
Atul Devatt Ayer, Richard L.-C. Yieh, Brenda J. Pollock, Patrick S.-L. Wong
Abstract: Osmotic delivery system semipermeable body assemblies that control the delivery rate of a beneficial agent from an osmotic delivery system incorporating one of the semipermeable body assemblies. A semipermeable body assembly or plug includes a semipermeable body which is positionable in an opening of an osmotic delivery system. The semipermeable body has a hollow interior portion having a size selected to obtain a predetermined liquid permeation rate through the semipermeable body. Because the beneficial agent in the osmotic delivery system is delivered at substantially the same rate the osmotic agent imbibes liquid which has permeated through the plug from a surrounding environment, the liquid permeation rate through the plug controls the delivery rate of the beneficial agent from the osmotic delivery system.
Type:
Grant
Filed:
July 24, 1998
Date of Patent:
September 11, 2001
Assignee:
Alza Corporation
Inventors:
Guohua Chen, Scott D. Lautenbach, Keith E. Dionne, Scott D. Jordan, Steve A. Berry, Craig I. Rodenberger, Rupal Ayer
Abstract: Performance of delivery systems for delivering beneficial agents to an animal are monitored to determine the delivery rate of the beneficial agent and the proper operation of the beneficial agent delivery device. Performance monitoring can be achieved by monitoring the physical configuration of the implanted osmotic delivery device from the exterior of the body to determine the amount of beneficial agent delivered and/or the delivery rate of the beneficial agent. The monitoring of the physical configuration of the implanted osmotic delivery device may be performed in different manners such as by X-ray or fluoroscopic monitoring of the implant structure or magnetic determination of a piston location within the implant. Performance monitoring can also be achieved by use of a performance marker within the beneficial agent to produce a specifically detectable response which can be measured noninvasively in body fluids or by-products.
Type:
Grant
Filed:
December 22, 1998
Date of Patent:
September 4, 2001
Assignee:
ALZA Corporation
Inventors:
Rupal Ayer, James B. Eckenhoff, Stephen A. Berry, Gregory R. Stewart, Scott D. Jordan
Abstract: An osmotic delivery system has a membrane plug retention mechanism which can also be used to control the delivery rate of a beneficial agent from the osmotic delivery system. The osmotic delivery device includes an implant capsule containing a beneficial agent and an osmotic agent. Holes are formed along a side wall of the implant capsule at an open end of the capsule. When the membrane plug is inserted into the open end of the capsule the membrane material swells into the holes in the capsule side wall creating a large frictional force which prevents expulsion of the membrane plug. A beneficial agent delivery rate of the osmotic delivery system is controllable by varying the size and number of the holes to change the amount of exposed surface area of the membrane plug. An increase in the surface area of the membrane plug exposed to the exterior environment causes a corresponding increase in the liquid permeation rate of the membrane and thus, increases the beneficial agent delivery rate.
Abstract: A percutaneous agent delivery or sampling device comprising a sheet having a plurality of microblades for piercing the skin for increasing transdermal flux of an agent. The microblades having a relatively sharp angled leading edge which transitions to a relatively gradually angled blade edge.
Type:
Grant
Filed:
June 17, 1997
Date of Patent:
May 8, 2001
Assignee:
Alza Corporation
Inventors:
Michel J. N. Cormier, Avtar S. Nat, Armand P. Neukermans, Barry Block
Abstract: A percutaneous agent sampling device and method are provided. The device comprises a collector and a sheet having a plurality of microblades for piercing the skin for increasing transdermal flux of an agent.
Type:
Grant
Filed:
June 17, 1997
Date of Patent:
April 17, 2001
Assignee:
Alza Corporation
Inventors:
Michel J. N. Cormier, Felix T. Theeuwes
Abstract: The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (e.g., fentanyl hydrochloride), preferably in a hydrogel formulation, for use in an electrotransport device (10). In accordance with the present invention, a transdermal electrotransport delivered dose of fentanyl/sufentanil is provided which is sufficient to induce analgesia in (e.g., adult) human patients suffering from moderate-to-severe pain as associated with major surgical procedures.
Type:
Grant
Filed:
March 17, 1998
Date of Patent:
April 10, 2001
Assignee:
Alza Corporation
Inventors:
Mary Southam, Keith J. Bernstein, Henk Noorduin
Abstract: The present invention relates generally to an electrotransport device for transdermally or transmucosally delivering a beneficial agent (e.g., a drug) to the body surface of a patient or for transdermally or transmucosally sampling a body analyte. Most particularly, the present invention relates to a configured and electrochemically reactive electrode assembly having improved start-up electrical performance and improved lag time to compliant agent delivery.